肽和拟肽作为治疗 COVID-19 的治疗候选物：简要综述。
Peptides and peptidomimetics as a therapeutic candidate for the treatment of COVID-19: A brief review.
机构信息
Department of Pharmacology, PGIMER, Chandigarh, India.
出版信息
Indian J Pharmacol. 2023 Jan-Feb;55(1):53-58. doi: 10.4103/ijp.ijp_700_22.
Abstract
Novel SARS-CoV-2 (COVID-19) is affecting worldwide as declared pandemic by the WHO. Various repositioning and novel therapeutic agents are being evaluated under different clinical setups; however, there is no promising therapeutic agent reported to date. Small molecules like peptides have their popularity as their specificity, delivery, and synthesizability as promising therapeutic agents. In this study, we have reviewed the published literature describing peptide designing, in silico binding mode, antiviral activity, preventive measures, and in vivo assessments. Here, we reported all the results which are promising against SARS-CoV-2 as therapeutic and preventive (vaccine candidates), and their status in the drug development process.
摘要
新型严重急性呼吸综合征冠状病毒 2（COVID-19）已在全球范围内传播，世界卫生组织已宣布其为大流行疾病。目前正在不同的临床环境下评估各种重新定位和新型治疗药物，但迄今为止尚未报告有疗效显著的治疗药物。小分子肽因其特异性、传递性和可合成性而备受关注，成为有前景的治疗药物。在本研究中，我们回顾了已发表的文献，这些文献描述了肽的设计、计算机模拟结合模式、抗病毒活性、预防措施和体内评估。在这里，我们报告了所有针对 SARS-CoV-2 的有前景的治疗和预防（候选疫苗）结果，以及它们在药物开发过程中的状态。
相似文献
1
Peptides and peptidomimetics as a therapeutic candidate for the treatment of COVID-19: A brief review.肽和拟肽作为治疗 COVID-19 的治疗候选物：简要综述。
Indian J Pharmacol. 2023 Jan-Feb;55(1):53-58. doi: 10.4103/ijp.ijp_700_22.
2
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.抗菌肽和其他类似肽的治疗药物作为对抗 SARS-CoV-2 的有希望的候选药物。
Expert Rev Anti Infect Ther. 2021 Oct;19(10):1205-1217. doi: 10.1080/14787210.2021.1912593. Epub 2021 Apr 12.
3
Development and Evaluation of Peptidomimetic Compounds against SARS-CoV-2 Spike Protein: An in silico and in vitro Study.针对 SARS-CoV-2 刺突蛋白的肽模拟化合物的开发和评估：一项计算机模拟和体外研究。
Mol Inform. 2022 Jul;41(7):e2100231. doi: 10.1002/minf.202100231. Epub 2022 Feb 1.
4
SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics?SARS-CoV-2 主蛋白酶抑制剂：肽和拟肽领域有哪些进展？
J Pept Sci. 2023 May;29(5):e3467. doi: 10.1002/psc.3467. Epub 2022 Dec 19.
5
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.关于在疫情爆发情况下治疗新型冠状病毒（SARS-CoV-2）的新兴治疗和预防策略的循证系统评价。
J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6):jbcpp-2020-0113. doi: 10.1515/jbcpp-2020-0113.
6
COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.新冠病毒：检测、治疗与疫苗研发的基础研究
Pharm Nanotechnol. 2020;8(4):323-353. doi: 10.2174/2211738508999200817163335.
7
Development and Prospects of Furin Inhibitors for Therapeutic Applications.furin 抑制剂治疗应用的开发与前景。
Int J Mol Sci. 2024 Aug 24;25(17):9199. doi: 10.3390/ijms25179199.
8
Harnessing the Therapeutic Potential and Biological Activity of Antiviral Peptides.利用抗病毒肽的治疗潜力和生物活性。
Chembiochem. 2022 Oct 19;23(20):e202200415. doi: 10.1002/cbic.202200415. Epub 2022 Sep 23.
9
Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.重新利用药物对抗 SARS-CoV-2 的主蛋白酶：基于机制的见解，得到了现有实验室和临床数据的支持。
Mol Omics. 2020 Oct 1;16(5):474-491. doi: 10.1039/d0mo00057d. Epub 2020 Jul 22.
10
A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.一种可转移的深度学习方法，用于快速筛选针对 SARS-CoV-2 的潜在抗病毒药物。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab211.
引用本文的文献
1
Peptide Inhibitor Assay for Allocating Functionally Important Accessible Sites Throughout a Protein Chain: Restriction Endonuclease EcoRI as a Model Protein System.用于在整个蛋白质链中定位功能重要可及位点的肽抑制剂分析：限制性内切核酸酶EcoRI作为模型蛋白质系统
BioTech (Basel). 2024 Dec 30;14(1):1. doi: 10.3390/biotech14010001.
本文引用的文献
1
SARS-CoV-2 M: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.SARS-CoV-2 M：肽模拟物和小分子抑制剂的潜在靶标。
Biomolecules. 2021 Apr 19;11(4):607. doi: 10.3390/biom11040607.
2
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.抗菌肽和其他类似肽的治疗药物作为对抗 SARS-CoV-2 的有希望的候选药物。
Expert Rev Anti Infect Ther. 2021 Oct;19(10):1205-1217. doi: 10.1080/14787210.2021.1912593. Epub 2021 Apr 12.
3
Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis.COVID-19 中类固醇治疗的疗效和安全性：快速系统评价和 Meta 分析。
Indian J Pharmacol. 2020 Nov-Dec;52(6):535-550. doi: 10.4103/ijp.ijp_1146_20.
4
Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.靶向 SARS-CoV-2 刺突蛋白的订书肽 hACE2。
Chem Commun (Camb). 2021 Apr 4;57(26):3283-3286. doi: 10.1039/d0cc08387a. Epub 2021 Mar 2.
5
Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection .基于人血管紧张素转化酶 2（ACE2）的订书肽强烈抑制 SARS-CoV-2 感染。
mBio. 2020 Dec 11;11(6):e02451-20. doi: 10.1128/mBio.02451-20.
6
Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.系统评价和荟萃分析法评估法匹拉韦在新型冠状病毒（COVID-19）患者管理中的疗效和安全性。
Indian J Pharmacol. 2020 Sep-Oct;52(5):414-421. doi: 10.4103/ijp.ijp_998_20.
7
Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2.针对不断变异的新型冠状病毒的肽抑制剂的适应性进化
Adv Theory Simul. 2020 Dec;3(12):2000156. doi: 10.1002/adts.202000156. Epub 2020 Oct 8.
8
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.整合素结合肽ATN-161作为治疗新型冠状病毒肺炎的新疗法
JACC Basic Transl Sci. 2021 Jan;6(1):1-8. doi: 10.1016/j.jacbts.2020.10.003. Epub 2020 Oct 16.
9
Inhibition of Coronavirus Entry and by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.脂肽抑制新型冠状病毒和严重急性呼吸综合征冠状病毒进入宿主细胞
mBio. 2020 Oct 20;11(5):e01935-20. doi: 10.1128/mBio.01935-20.
10
Peptides: Prospects for Use in the Treatment of COVID-19.肽：在 COVID-19 治疗中的应用前景。
Molecules. 2020 Sep 24;25(19):4389. doi: 10.3390/molecules25194389.
Zotero 插件